Catalog No.
Product Name
Application
Product Information
Citations
-
c-MET inhibitor
Foretinib (GSK1363089), a multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces Anoikis, and impairs ovarian cancer metastasis.- Ayaka Kojima, .et al. , Xenobiotica, 2022, Jul;52(7):669-675 PMID: 36251932
- Narges K Gortany, .et al. , Cancer Chemother Pharmacol, 2021, Mar 10 PMID: 33688998
- Hamzehlou S, .et al. , Eur J Pharmacol, 2019, Nov 15;863:172705 PMID: 31574259
- Hayato Ogura, .et al. , Sci Rep, 2017, 7: 5519 PMID: 28717217
- Fuse MJ, .et al. , Mol Cancer Ther, 2017, Oct;16(10):2130-2143 PMID: 28751539
- Ryohei Katayama, .et al. , Clin Cancer Res, 2015, Jan 1; 21(1): 166-174 PMID: 25351743
-
c-Met/NPM-ALK inhibitor
Crizotinib is inhibitor of the c-Met kinase and the NPM-ALK.- Brittany M. Duggan, .et al. , Sci Rep, 2017, 7: 1578 PMID: 28484277
-
c-MET inhibitor
LY2801653 is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM).- Jennifer Huang, .et al. , Cells, 2026, 15(3): 285 PMID: 41677648
- Ji-Eun Kim, .et al. , Immunity, 2022, Dec 13;55(12):2300-2317 PMID: 36473468
-
IGF-1R inhibitor
BMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.- Li Li, .et al. , Leukemia Res, 2019, 78:12-20 PMID: 30660961
-
c-MET Inhibitor
INCB28060, a novel inhibitor of c-MET kinase. INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases. This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines.- Liyanage Manosika Buddhini Perera, .et al. , Biol Pharm Bull, 2024, 47(4):750-757 PMID: 38556260
- Geoffrey A Pettitt, .et al. , J Pathol, 2023, Feb;259(2):220-232 PMID: 36385700
-
VEGFR inhibitor
XL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2.- Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
- Jhe-Cyuan Guo, .et al. , Journal of Clinical Oncology, 2024, May 29
- Feyza Oflaz, .et al. , Cumhuriyet Sci. J., 2023, 44(4): 650-655
- Fujita KI, .et al. , J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
-
multiple receptor tyrosine kinases inhibitor
Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.- Paula Sagmeister, .et al. , J Hepatocell Carcinoma, 2022, Jul 9;9:595-607 PMID: 35845819
- Aya Hasan Alshammari, .et al. , Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
-
ALK/ c-Met inhibitor
PF-2341066 (Crizotinib) is an inhibitor of the c-Met kinase and the NPM-ALK. PF-2341066 inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM).- Sang-Yun Lee, .et al. , J Exp Clin Cancer Res, 2023, Nov 22;42(1):309 PMID: 37993887
- Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
- Yu B, .et al. , J Sep Sci, 2020, Jan 22 PMID: 31970927
- Li Li, .et al. , Leukemia Res, 2019, 78:12-20 PMID: 30660961
- Li T, .et al. , Oncogene, 2018, Nov;37(47):6180-6194 PMID: 30013190
- Saki Omote, .et al. , Sci Rep, 2018, 8: 9237 PMID: 29915248
- Arakawa H, .et al. , J Pharm Sci, 2017, Sep;106(9):2899-2903 PMID: 28336299
-
c-Met inhibitor
ARQ-197 is a selective inhibitor of the c-Met receptor tyrosine kinase- Wang L, .et al. , J Am Chem Soc, 2019, Aug 14;141(32):12673-12681 PMID: 31381313
- Koide H, .et al. , Xenobiotica, 2018, Oct;48(10):1059-1071 PMID: 29034773
-
c-Met inhibitor
BMS-777607 is a MET tyrosine kinase inhibitor that binds to c-Met protein, or HGFR, preventing binding of HGF and disrupting the MET signaling pathway. -
c-Met inhibitor
BMS-794833 is a potent ATP competitive inhibitor to Met and VEGFR-2 with IC50 of 1.7 and 15 nmol. -
c-Met inhibitor
c-Met inhibitor JNJ-38877605 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. -
c-Met inhibitor
MGCD265 is a multitargeted tyrosine kinase inhibitor that binds to and inhibits the phosphorylation of several RTKs, including the c-Met receptor (HGFR); the Tek/Tie-2 receptor; VEGFR types 1, 2, and 3; and MST1R. -
c-Met Inhibitor
PF-04217903 is a novel c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitors. -
c-Met Inhibitor
PHA665752 is a small-molecule inhibitor of c-Met/HGF/SF signaling. -
VEGFR/c-Met/HGFR inhibitor
TAS-115 is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. -
triplex matriptase inhibitor
SRI 31215 (TFA), a triplex inhibitor of matriptase, hepsin and hepatocyte growth factor activator (HGFA) with IC50s of 0.69 μM, 0.65 μM, 0.3 μM, blocks pro-HGF activation and thus mimics the activity of HAI-1/2. -
dual c-Met/Ron inhibitor
MK8033 Hcl is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer. -
dual inhibitor for c-Met and EGFR
Norcantharidin (Endothall anhydride) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers. -
c-Met/HGFR inhibitor
TAS-115 mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. -
multi-targeted tyrosine kinase inhibitor
Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. -
MET Degrader
PRO-6E is a PROTAC that targets Cereblon to induce degradation of the MET protein. It achieves up to 81.9% degradation of MET at 1 μM in MKN-45 cells, effectively inhibiting tumor growth both in vitro and in vivo. Additionally, PRO-6E promotes apoptosis and cell cycle arrest, making it a valuable tool for research on MET-related oncogenic processes. -
PROTAC degrader
SJF-8240 (PROTAC 7) is a proteolysis-targeting chimera (PROTAC) designed to selectively degrade the receptor tyrosine kinase c-Met. It induces polyubiquitination and subsequent proteasomal degradation of c-Met, leading to effective inhibition of downstream signaling. SJF-8240 exhibits potent antiproliferative activity in GTL16 gastric cancer cells, with an IC₅₀ of 66.7 nM, making it a promising tool for targeted cancer therapy and c-Met–driven tumor research. -
PI3Kα/c-Met Inhibitor
DFX117 is a selective, orally active inhibitor targeting PI3Kα and c-Met tyrosine kinase. This compound effectively inhibits the PI3K/Akt/mTOR pathway, demonstrating significant antiproliferative activity against cancer cell lines such as NCI-H1975, NCI-H1993, and HCC827, with IC50 values ranging from 0.02 to 0.08 µM. DFX117 induces cell cycle arrest at the G0/G1 phase and promotes apoptosis in A549 and NCI-H1975 cells. Additionally, DFX117 exhibits notable antitumor efficacy in murine models, making it a valuable tool for cancer research. -
c-MET Kinase Inhibitor
Capmatinib hydrochloride is a selective c-MET kinase inhibitor that competitively targets ATP (IC50 = 0.13 nM). It effectively inhibits the phosphorylation of c-MET and its downstream signaling pathways, including ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib hydrochloride demonstrates potent antitumor activity by inhibiting c-MET-dependent tumor cell proliferation and migration, as well as inducing apoptosis. This compound is primarily metabolized by CYP3A4 and aldehyde oxidase, making it relevant for studies in cancer research and therapeutic development. -
c-MET Inhibitor
ABN401 is a selective ATP-competitive inhibitor of c-MET, exhibiting an IC50 of 10 nM. This compound demonstrates cytotoxic effects on MET-addicted cancer cells, with IC50 values ranging from 2 to 43 nM. ABN401 has shown oral bioavailability in preclinical models, with 42.1% to 56.2% in rats and 27.4% to 37.7% in dogs, and possesses significant antitumor activity, making it a valuable tool for cancer research and therapeutic development. -
EGFR/c-Met Inhibitor
EGFR/c-Met-IN-1 is a dual inhibitor targeting both EGFR and c-Met, with IC50 values of 68.1 nM for EGFRL858R and 0.26 nM for c-Met. This compound induces apoptosis and causes cell cycle arrest in A549-P cells by downregulating the phosphorylation of EGFR, c-Met, and downstream AKT pathways. EGFR/c-Met-IN-1 demonstrates significant tumor growth inhibition in vitro and in vivo, making it a valuable reagent for cancer research focused on targeting these pathways. -
EGFR/c-Met Inhibitor
EGFR-IN-8 is a dual inhibitor of the epidermal growth factor receptor (EGFR) and c-Met, demonstrating potential efficacy against EGFR TKI-resistant non-small cell lung cancer (NSCLC). This compound offers a novel approach for effectively targeting resistance mechanisms in NSCLC, providing a valuable tool for oncological research and drug development. Its unique pharmacological profile positions it as a promising candidate for further investigation in cancer therapy. -
c-Met inhibitor
c-met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC50 of 1.1 nM, with antitumor activity. -
c-Met/VEGFR inhibitor
Altiratinib is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro. -
c-Met inhibitor
Volitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. -
tyrosine kinase inhibitor
Ningetinib is a multi-kinase inhibitor that inhibits c-Met, VEGFR2/KDR, and Axl with IC50s value of 19, 37, and 11 nM, respectively. - Sodium succinate dibasic is an inhibitor of multiple receptor tyrosine kinases. Sodium succinate dibasic is known to be a potent inhibitor of Met, Flt-1 (VEGFR1), Flk-1 (VEGFR2), Flt-3 (VEGFR3), Ron, and Tie-2. Sodium succinate dibasic has been observed to inhibit Met (c-Met)-driven tumor cell and non-c-Met driven tumor cell (HCT116 and MDA-MB-231) proliferation. This product has also been observed to effectively inhibit c-Met phosphorylation and its downstream signaling pathways in serum starved MKN45 cells, as well as inducing apoptosis in these cells.
-
c-Met inhibitor
JNJ-38877618 is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor with Kd of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively. -
c-Met inhibitor
Glumetinib (SCC244) is a potent and highly selective c-Met kinase inhibitor with an IC50 of 0.42 nM. Glumetinib shows antitumor activity and a superior safety margin. -
ALK/MET inhibitor
Ensartinib (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. -
c-Met inhibitor
c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC50 of 0.6 nM, with antitumor activity. -
c-Met inhibitor
c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.
